Vacchi et al., 2020 - Google Patents
Tau and alpha synuclein synergistic effect in neurodegenerative diseases: When the periphery is the coreVacchi et al., 2020
View HTML- Document ID
- 14029850159911104287
- Author
- Vacchi E
- Kaelin-Lang A
- Melli G
- Publication year
- Publication venue
- International journal of molecular sciences
External Links
Snippet
In neuronal cells, tau is a microtubule-associated protein placed in axons and alpha synuclein is enriched at presynaptic terminals. They display a propensity to form pathologic aggregates, which are considered the underlying cause of Alzheimer's and Parkinson's …
- 102000003802 alpha-Synuclein 0 title abstract description 103
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vacchi et al. | Tau and alpha synuclein synergistic effect in neurodegenerative diseases: When the periphery is the core | |
Bolus et al. | Modeling neurodegenerative disorders in Drosophila melanogaster | |
Mroczko et al. | The role of protein misfolding and tau oligomers (TauOs) in Alzheimer’s disease (AD) | |
Schaffert et al. | Do post-translational modifications influence protein aggregation in neurodegenerative diseases: a systematic review | |
Longhena et al. | Living in promiscuity: the multiple partners of alpha-synuclein at the synapse in physiology and pathology | |
Rockenstein et al. | Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo | |
Kovacs | Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine | |
Medina et al. | New features about tau function and dysfunction | |
Bendor et al. | The function of α-synuclein | |
Aiken et al. | The α-tubulin gene TUBA1A in brain development: a key ingredient in the neuronal isotype blend | |
Gusella et al. | Huntington's disease: seeing the pathogenic process through a genetic lens | |
Madsen et al. | Interaction between Parkin and α-synuclein in PARK2-mediated Parkinson’s disease | |
Hasegawa | Molecular mechanisms in the pathogenesis of Alzheimer’s disease and tauopathies-prion-like seeded aggregation and phosphorylation | |
Dani et al. | A targeted glycan-related gene screen reveals heparan sulfate proteoglycan sulfation regulates WNT and BMP trans-synaptic signaling | |
Alvarez et al. | Modeling Alzheimer’s disease in caenorhabditis elegans | |
Candelise et al. | Protein aggregation landscape in neurodegenerative diseases: Clinical relevance and future applications | |
Hayashi et al. | β-Synuclein: An enigmatic protein with diverse functionality | |
Tamaki et al. | Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD | |
Fan et al. | Alpha-synuclein and cognitive decline in Parkinson disease | |
Oláh et al. | Microtubule-associated proteins with regulatory functions by day and pathological potency at night | |
Ruiz-Gabarre et al. | What’s in a gene? The outstanding diversity of MAPT | |
Olesnicky et al. | Drosophila as a model for assessing the function of RNA-binding proteins during neurogenesis and neurological disease | |
Giong et al. | Non-rodent genetic animal models for studying tauopathy: review of Drosophila, zebrafish, and C. elegans models | |
Carroll et al. | Tau post-translational modifications: potentiators of selective vulnerability in sporadic Alzheimer’s disease | |
Gagliardi et al. | Stathmins and motor neuron diseases: pathophysiology and therapeutic targets |